European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Sponsored by Astellas Pharma Europe Ltd.
About this trial
Last updated 8 months ago
Study ID
9785-MA-1002
Status
Completed
Type
Observational
Placebo
No
Accepting
All
Male
Not accepting
Healthy Volunteers
Trial Timing
Ended 6 years ago
What is this trial about?
The purpose of this study is to evaluate the effectiveness of enzalutamide in patients
with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice
setting as measured by time to treatment failure defined as the time from baseline
(treatment initiation) to treatment discontinuation of enzalutamide for any reason
including disease progression, skeletal related events, treatment toxicity, patient
preference, or death.
What are the participation requirements?
Inclusion Criteria
- Men with mCRPC who have been prescribed enzalutamide as part of standard clinical practice
- Germany only: Enzalutamide will be prescribed according to the current SmPC (Summary of Product Characteristics)
Exclusion Criteria
- Patients with the following will be excluded from study participation in France only:
- Patients who have previously been treated with abiraterone acetate (Zytiga®) after docetaxel chemotherapy.
- Patients who have previously been treated with cabazitaxel (Jevtana®)
- Patients who have previously been treated with Xtandi®
- Patients taking part in an interventional clinical trial